Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

AV-23-001 AVAVA MIRIA pilotstudie

9 november 2026 bijgewerkt door: AVAVA, Inc.

This non-significant risk study is intended to demonstrate the use of the MIRIA Skin Treatment System can show improvement in dermatologic conditions currently indicated for treatment with a laser (such as, but not limited to, benign pigmented lesions, benign cutaneous lesions, wrinkles, textural irregularities, or scars). The study is also intended to assist in determination of the optimal laser configuration and treatment parameters that most consistently yield results.

Studie Overzicht

Gedetailleerde beschrijving

This study is intended to allow clinical evaluation of the feasibility of the MIRIA Skin Treatment System, referred to herein as the SR Skin Rejuvenation Laser, for the treatment of dermatologic conditions currently indicated for treatment with a laser (such as, but not limited to, benign pigmented lesions, benign cutaneous lesions, wrinkles, textural irregularities, or scars). This clinical evaluation is being performed under an investigational protocol to formally collect data for the treatment of different dermatologic conditions.

This prospective, non-randomized, controlled study will include subjects with dermatologic conditions that are currently indicated for treatment with a laser who are willing to have sites exposed to the MIRIA Laser and who agree to comply with the study requirements during the follow-up period, a minimum of 3 months and a maximum of 18 months. Some areas with the dermatologic condition may be left as a control for the treated section. Subjects may also be directed to use some topical cream or lotion for up to 1 month prior to the laser procedure or during the duration of the study, according to the Investigator's standard practice.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

10

Fase

  • Niet toepasbaar

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • New York
      • Dix Hills, New York, Verenigde Staten, 11746
        • Skinfluence Long Island
      • New York, New York, Verenigde Staten, 10010
        • Laser and Skin Surgery Center of New York

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Ja

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Male or female subjects > 18 years of age.

  2. Dermatologic condition currently indicated for laser treatment OR the subject is to be enrolled for assessment of treatment parameters on normal skin.

  3. Willingness to have multiple areas exposed.

  4. Willingness to have digital photographs taken of treatment area(s) and agreement with use of photographs for presentation, educational, or marketing purposes.

  5. Willingness to comply with the following during the study, including the follow-up period:

    1. maintain consistent skin care regimen on treated areas.
    2. Willingness to cover treated areas or have very limited sun exposure and, if requested, use an approved sunscreen of SPF 50 or higher.
    3. refrain from using systemic corticosteroids, according to Investigator discretion.
    4. refrain from using topical corticosteroids, retinoids, or prescription skin-lightening medications on the treated areas, according to Investigator discretion.
    5. refrain from any other procedures in the treatment areas.
  6. Willingness and ability to comply with study instructions and return for required visits.

  7. Subject understands that fees will be collected at the time of treatment ranging from $300 to $3000 per treatment depending upon number of anatomical areas treated. The exact amount will be disclosed and recorded within the consent.

  8. Subject has read and signed a written informed consent form.

  9. Subject lives within 50 miles of study site.

  10. For Males: Willingness to shave facial hair on treatment areas.

    Exclusion Criteria:

  11. Skin pathology or condition that could interfere with evaluation of the study procedure, e.g.,

  12. Systemic treatment prescribed within previous 6 months (e.g., oral medication such as isotretinoin)

  13. Surgical treatment in the target areas within previous 6 months (e.g., laser surgery)

  14. Active vitiligo, psoriasis, or eczema in the treatment area

  15. The timing of use of fillers, neuromodulators and other cosmetic procedures are at the discretion of the investigator.

  16. Topical treatment applied to target areas within the previous 1 month or according to Investigator discretion.

  17. Active suntan and unable or unlikely to refrain from tanning within the follow-up period.

  18. Artificial tanning in the target areas within the previous 1 month (e.g., spray, lotion, tanning bed) or intention to use artificial tanning within the follow-up period.

  19. Active localized or systemic infection, or an open wound in area being treated.

  20. Lesions in the treatment areas suspicious for malignancy (skin cancer, melanoma)

  21. History of abnormal wound healing or abnormal scarring (e.g., hypertrophic or keloid)

  22. History of connective tissue disease, such as lupus or scleroderma.

  23. Any use of medication that is known to increase sensitivity to light according to Investigator's discretion (e.g., topicals that produce sensitivity to light may be used in areas other than the target area).

  24. History of gold therapy.

  25. History of disease stimulated by heat, such as recurrent herpes simplex or herpes zoster (shingles) in the treatment area, unless treatment is conducted following a prophylactic regimen.

  26. History of radiation to the treatment area or currently undergoing systemic chemotherapy for the treatment of cancer.

  27. For Female: Pregnancy or lactation, or intent to become pregnant within the study period.

  28. Significant uncontrolled concurrent illness, such as diabetes mellitus or cardiovascular disease, e.g., uncontrolled hypertension.

  29. History of immunosuppression/immune deficiency disorder or currently using immunosuppressive medications.

  30. Current enrollment in a clinical study of any other unapproved investigational drug or device unless it is a noninvasive dermal study for which the subject is in a follow-up period and has other areas of skin that meet the study criteria or has received an investigational drug or been treated with an investigational device within 30 days prior to entering this study.

  31. Any other condition or laboratory value that would, in the professional opinion of the investigator, potentially affect response or participation in this clinical study, or would pose an unacceptable risk to the subject.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Behandeling
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: Treated Cohort

Experimental: Treatment with the MIRIA Laser 3-4 experimental treatments at 4-6 week intervals. Refine usage of device

The MIRIA Skin Treatment System is a 1550nm-based laser system indicated for use in dermatologic procedures requiring the coagulation of soft tissue, as well as for skin resurfacing procedures.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Global Aesthetic Improvement Scale (GAIS)
Tijdsspanne: 3 Months

Scale used to compare before and after images of subjects treated. Scores include the following:

  1. - Very Much Improved
  2. - Much Improved
  3. - Improved
  4. - No Change
  5. - Worse
3 Months

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Subject Questionnaire
Tijdsspanne: Immediate Post Treatment, 3 Months Post Treatment

Questionnaire that evaluates the subjects impression of the treatment (overall discomfort score, satisfaction with treatment results, notes on treatment sensation).

Immediate Post Treatment, 3 Months Post Treatment
Adverse Event Assessment
Tijdsspanne: Immediate Post Treatment, 3 Months Post Treatment

An assessment of side effects and adverse event profile to ensure safety of treatment. Data collected included the event, the duration, the severity, and any other interventions that may occur due to the adverse event.

Immediate Post Treatment, 3 Months Post Treatment

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Hoofdonderzoeker: Hyemin Pomerantz, MD, AVAVA, Inc.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

6 november 2023

Primaire voltooiing (Werkelijk)

3 juli 2024

Studie voltooiing (Werkelijk)

3 juli 2024

Studieregistratiedata

Eerst ingediend

11 december 2023

Eerst ingediend dat voldeed aan de QC-criteria

13 augustus 2024

Eerst geplaatst (Werkelijk)

16 augustus 2024

Updates van studierecords

Laatste update geplaatst (Werkelijk)

10 november 2026

Laatste update ingediend die voldeed aan QC-criteria

9 november 2026

Laatst geverifieerd

1 november 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

NEE

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Ja

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren